About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The VHIR Infectious Diseases research group is made up of medical professionals, with healthcare and clinical or basic translational research activities; of Biomedicine dedicated to basic research; and Nursing, with activities to support clinical research.
The group's lines of research are mainly focused on four areas:
Infections related to immunosuppression. Includes infectious diseases related to immunocompromised patients, solid organ or hematopoietic stem cell transplant recipients and recipients of biological therapies.
Sexually transmitted diseases, including HIV infection and other highly prevalent infections in our country (syphilis, gonorrhea, lymphogranuloma venere or infections caused by the human papillomavirus).
Infections related to health care, with special emphasis on those difficult to treat (cardiovascular infections or infections related to prosthetic materials) or caused by multi-resistant pathogens (MDRO) or affecting vulnerable populations.
Global Health and Tropical Diseases with special emphasis on prevalent diseases in our environment that affect the immigrant or displaced population.
IP: Israel Molina Romero Collaborators: Pau Bosch Nicolau Funding agency: Instituto de Salud Carlos III Funding: 135520 Reference: PI22/01894 Duration: 01/01/2023 - 30/06/2027
IP: Israel Molina Romero Collaborators: Maria Luisa Aznar Ruiz de Alegria, Laia Perez Lasarte Funding agency: Instituto de Salud Carlos III Funding: 180000 Reference: JR21/00027 Duration: 26/05/2022 - 25/05/2026
IP: Fernando M Salvador Velez Collaborators: - Funding agency: Sdad Española Enferm Infec Microb Clínica SEIMC Funding: 65084.91 Reference: SEIMC/PROJECTEINVEST/2020/SALVADOR Duration: 15/01/2021 - 15/07/2026
IP: Israel Molina Romero Collaborators: Maria Luisa Aznar Ruiz de Alegria, Bibiana Planas Ribas, Marta Sanchiz Cruz, Esperanza Esteban Serna, Josep Roca Grande, Ana Castiella Garcia, Jose Cabral Jamba , Tayná Marques Torres Barboza Funding agency: EUROPEAN COMMISSION Funding: 3004510.89 Reference: CRESCER_I.MOLINA_EUROPEAID_2019 Duration: 15/02/2021 - 14/10/2026
Women have a mortality rate of 21% during the 30 days following surgery, compared with 11% in men, a difference that remains after taking patients’ clinical characteristics into account.
The DETECTIVE doctoral network, coordinated by the University of Turku and funded by the Marie Skłodowska-Curie Actions of the Horizon Europe programme, will train 14 predoctoral researchers in five countries.
The initiative focuses on awareness, prevention, and the normalization of sexual health check-ups among young people.
